Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

NCT05477576 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT05477576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05477576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
Lead sponsor
RayzeBio, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 24, 2022
Completion date
December 31, 2030
Enrollment
343 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, carcinoid tumor, gastroenteropancreatic neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumor disease, gep-net, neuroendocrine tumors, pancreatic net